col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


43 Results       Page 1

 [1] 
Geotar-Media Publishing Group: Immunologiya
  original article Date Title Authors   All Authors
1 [GO] 2025―Feb―28 Sequencing of Ig genes from single circulating plasmablasts during acute SARS-CoV-2 infection M.G. Byazrova, M.M. Sukhova, A.A. Mikhailov, P.P. Guseva, A.F. Romanova, A.G. Prilipov, A.V. Filatov
2 [GO] 2025―Feb―28 Significance of cytokines of convalescent plasma for survival of recipients treated for COVID-19. Effects on clinical and laboratory data M.P. Potapnev, A.V. Maximovich, I.A. Dunayeu, L.M. Hushchina, F.N. Karpenko, O.V. Krasko
3 [GO] 2024―May―23 HLA-A, -B, -DRB1 genes polymorphism of in COVID-19 patients E.M. Rodnikova, K.R. Dudina, T.E. Yankevich, V.V. Kadochnikova, M.N. Boldyreva, D.Yu. Trofimov
4 [GO] 2024―May―23 Exploring potential biomarkers for predicting COVID-19 severity and outcome N.N. Sushentseva, O.S. Popov, S.V. Apalko, A.Yu. Asinovskaya, S.V. Mosenko, A.M. Sarana, S.G. Shcherbak
5 [GO] 2024―Mar―12 Study of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2 R.I. Ataullakhanov, E.I. Ushakova, A.V. Pichugin, E.S. Lebedeva, S.V. Ivanov, T.A. Ozharovskaia, et al. (+8)
6 [GO] 2024―Jan―26 Dynamics and functional characteristics of antibodies and memory B cells to SARS-CoV-2 in peripheral blood from COVID-19 patients for up to 16 months I.S. Vladimirov, A.S. Zhdanova, E.S. Bolashova, V.E. Mukhin, V.V. Makarov, V.S. Yudin, S.A. Kraevoy
7 [GO] 2024―Jan―26 Features of cell immunity of healthcare workers in the first wave of the SARS-CoV-2 infection pandemic A.A. Borunova, E.K. Shoua, E.N. Zakharova, A.I. Chertkova, Z.G. Kadagidze, I.B. Shoua, et al. (+9)
8 [GO] 2023―Dec―14 Study of the antigenic specificity of T-cell immune reactions in response to immunization of laboratory mice with a recombinant adenoviral vector encoding the Spike-protein of SARS-CoV-2 R.I. Ataullakhanov, E.I. Ushakova, A.V. Pichugin, E.S. Lebedeva, S.V. Ivanov, T.A. Ozharovskaia, et al. (+8)
9 [GO] 2023―Sep―25 Evaluation of the efficacy of different adjuvants in producing murine monoclonal antibodies to the receptor-binding domain of the S-protein of SARS-CoV-2 T.A. Ivashchenko, Ya.O. Romanenko, M.A. Marin, A.S. Kartseva, M.V. Silkina, N.A. Zeninskaya, et al. (+2)
10 [GO] 2023―Aug―04 MIR 19® - world first specific antiviral drug for COVID-19 treatment: development and preclinical studies M.R. Khaitov, A.A. Nikonova, I.P. Shilovskiy, K.V. Kozhikhova, I.A. Kofiadi, G.O. Gudima, et al. (+24)
11 [GO] 2023―Aug―04 Cellular and humoral responses to SARS-CoV-2 (omicron variant) in children and adolescents with pulmonary tuberculosis M.M. Averbakh, L.V. Panova, E.S. Ovsyankina, A.E. Ergeshov, T.G. Smirnova, E.A. Kiseleva, et al. (+2)
12 [GO] 2023―May―29 Dynamics of clinical and immunological parameters in patients underwent a moderate COVID-19 and received therapy with janus kinase inhibitor L.P. Sizyakina, N.A. Skripkina, E.A. Antonova, D.P. Sizyakin
13 [GO] 2023―May―29 Dynamic assessment of the intensity of the immune response to SARS-CoV-2 infection and immunization against COVID-19 with the vaccine «Sputnik V» K.O. Nechay, A.I. Andreev, I.V. Andreev, D.R. Esaulova, O.S. Baklakova, M.B. Shadyzheva, et al. (+10)
14 [GO] 2023―Mar―17 Changes in the expression of genes encoding ACE2 and innate immunity molecules (TLR7, IFN-α, IL-1β, TNF) in elderly patients with COVID-19 V.V. Grechenko, O.S. Uvarova, T.V. Gromova, O.V. Artemyeva, L.V. Gankovskaya
15 [GO] 2023―Mar―17 Humoral immune response to linear and conformational epitopes of SARS-CoV-2 in patients with COVID-19 V.A. Shokina, D.S. Matyushkina, D.V. Krivonos, V.A. Manuvera, D.A. Shirokov, D.D. Kharlampieva, et al. (+26)
16 [GO] 2023―Mar―17 Impact of SARS-CoV-2-specific cellular and humoral immunity on survival in patients with COVID-19 for the first time O.S. Popov, N.N. Sushentseva, I.A. Polkovnikova, S.V. Apalko, A.Yu. Rudnik, A.Yu. Anisenkova, et al. (+4)
17 [GO] 2023―Mar―17 Severe asthma and COVID-19 in a real clinical practice G.R. Sergeeva, A.V. Emelyanov, I.V. Tsukanova, E.V. Leshenkova, A.A. Znakhurenko
18 [GO] 2023―Mar―17 Methodology for evaluation of the level of IgG antibodies against different SARS-CoV-2 proteins using multiplex immunofluorescence analysis L.V. Frolova, P.Yu. Zemsky, S.I. Mitrofanov, V.E. Mukhin, T.А. Shpakova, P.G. Kazakova, et al. (+15)
19 [GO] 2022―Nov―14 The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19 A.A. Soldatov, Zh.I. Avdeeva, D.V. Gorenkov, L.M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, et al. (+2)
20 [GO] 2022―Nov―14 Сorrelation between age and the intensity of the post-vaccination humoral immune response in individuals passed COVID-19 A.I. Andreev, I.V. Andreev, K.O. Nechay, D.R. Esaulova, O.S. Baklakova, V.I. Vecherko, et al. (+7)
21 [GO] 2022―Nov―14 Clinical and immunological characteristics of the postcovid period in patients with moderate-severe COVID-19 who received therapy with the inclusion of an IL-6 receptor antagonist L.P. Sizyakina, N.A. Skripkina, E.A. Antonova, D.P. Sizyakin
22 [GO] 2022―Sep―16 «Storm» of soluble differentiation molecules in COVID-19 V.V. Novikov, A.V. Karaulov
23 [GO] 2022―Sep―16 Features of postinfectious immunity formation in a patient with common variable immune deficiency and severe COVID-19 course: a description of a clinical case L.P. Sizyakina, I.I. Andreeva, N.A. Skripkina
24 [GO] 2022―Jul―18 Interferon system for COVID-19 A.N. Narovlyansky, F.I. Ershov, A.V. Sanin, A.V. Pronin
25 [GO] 2022―Jul―18 Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19 P.A. Talyzin, A.L. Myasnikov, S.A. Berns, M.A. Ilyina, A.A. Komazov, V.S. Lynyov, E.V. Ekusheva
26 [GO] 2022―Jul―18 Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19 (in Russian) P.A. Talyzin, A.L. Myasnikov, S.A. Berns, M.A. Ilyina, A.A. Komazov, V.S. Lynyov, E.V. Ekusheva
27 [GO] 2022―May―16 Cytokine patterns of fatal hyperinflammatory conditions, caused by secondary hemophagocytic lymphohistiocytosis, bacterial sepsis and COVID-19 M.Yu. Pervakova, V.G. Potapenko, O.Yu. Tkachenko, E.V. Volchkova, O.N. Titova, S.V. Lapin, et al. (+14)
28 [GO] 2022―May―16 Anosmia in COVID-19 and allergic rhinitis. Effect of masking on the severity of symptoms A.I. Shcherbakov, O.A. Stukolova, A.V. Tutelyan, A.A. Ploskireva, V.G. Akimkin
29 [GO] 2022―May―16 Dynamics of immune status parameters in patients with COVID-19, receiving therapy with inclusion of an IL-6 receptor antagonist L.P. Sizyakina, N.A. Skripkina, E.A. Antonova, V.Ya. Zakurskaya, D.P. Sizyakin
30 [GO] 2022―May―16 Immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome I.M. Osmanov, I.M. Khegai, I.I. Trunina, T.A. Chebotareva, A.A. Cheburkin, P.V. Shumilov
31 [GO] 2022―Apr―11 Dynamics of specific humoral response in COVID-19 patients V.Ya. Zakurskaya, L.P. Sizyakina, M.V. Kharitonova, S.V. Shlyk
32 [GO] 2022―Apr―11 Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection I.V. Andreev, K.O. Nechay, A.I. Andreev, A.P. Zubaryova, D.R. Esaulova, A.M. Alenova, et al. (+18)
33 [GO] 2021―Nov―23 Ferritin level as a predictor of COVID-19 severe course L.P. Sizyakina, V.Ya. Zakurskaya, N.A. Skripkina, E.A. Antonova
34 [GO] 2021―Sep―13 Clinical and immunological correlations in COVID-19: experience of immunomodulatory therapy T.V. Khorobryh, G.K. Makhnach, M.V. Volgin, V.V. Khorobryh, N.P. Mishchenko, A.A. Ivashchenko, et al. (+2)
35 [GO] 2021―Jul―23 Changes in the expression of Toll-like receptors, cytokines and chemokines in the cells of the mucous membrane of the oropharynx in children with COVID-19 L.V. Gankovskaya, E.V. Zinina, V.A. Gankovskii, A.R. Semushkin
36 [GO] 2021―Jul―23 COVID-19 in children with bronchial asthma: clinical manifestations, course options, approaches to therapy N.A. Geppe, N.G. Kolosova, M.D. Shakhnazarova, A.B. Malakhov, Yu.S. Timofeev, V.G. Samartseva, et al. (+5)
37 [GO] 2021―Jul―23 Possible role of anti-IL17 drugs in the management of COVID-19: our own experience and literature review E.A. Shatokhina, A.S. Polonskaia, E.A. Mershina, E.M. Seredinina, A.G. Plisyuk, O.A. Georginova, et al. (+6)
38 [GO] 2021―Jul―23 Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection G.O. Gudima, R.M. Khaitov, D.A. Kudlay, M.R. Khaitov
39 [GO] 2021―Feb―01 Prophylaxis of medium and severe clinical forms of COVID-19 infection with aminodihydrophtalazindione sodium salt (Galavit®) in medical personnel working in the «red zone» Sergey V. Kolesov, Dmitry S. Gorbatyuk, Andrey A. Panteleyev, Alexey I. Bernakevich, Konstantin Yu. Ukolov
40 [GO] 2020―Aug―18 SARS-CoV-2 virus and other epidemic coronaviruses: pathogenetic and genetic factors for the development of infections M.N. Boldyreva
41 [GO] 2020―Aug―18 A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV A.V. Kovyrshina, I.V. Dolzhikova, D.M. Grousova, M.V. Balyasin, A.G. Botikov, L.V. Panina, et al. (+16)
42 [GO] 2020―Jun―24 Immune response against epidemic coronaviruses M.V. Pashenkov, R.M. Khaitov
43 [GO] 2020―Jun―24 Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy M.P. Kostinov
 [1] 

43 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.014 sec